Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04197934 · ClinicalTrials.gov registry record · Phase 1

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

A Phase 1 study of Stage IV Lung Cancer AJCC v8 and Metastatic Lung Non-Small Cell Carcinoma, sponsored by Mayo Clinic.

Active
Registry status
Phase 1
Development phase
56
Enrollment target
3
Study locations

NCT04197934 is a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Metastatic Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 56 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (43% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04197934, a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Metastatic Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
3
Study locations

Study Summary

This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers. Funding Source - FDA OOPD

Conditions Studied

Stage IV Lung Cancer AJCC v8 Metastatic Lung Non-Small Cell Carcinoma Glioblastoma, IDH-wildtype Metastatic Malignant Neoplasm in the Central Nervous System Anaplastic Astrocytoma, IDH-Wildtype

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Biospecimen Collection - blood samples
  • PROCEDURE Biospecimen Collection - CSF samples
  • DRUG EGFR/EGFRvIII Inhibitor WSD0922-FU

Study Locations (3)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2019-12-20
Est. Completion 2031-02-06
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04197934

The ClinicalTrials.gov registry entry for NCT04197934 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (43% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT04197934 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04197934 about?

NCT04197934 is a clinical study titled "WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases". This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR...

What is the current status of trial NCT04197934?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-12-20. Estimated completion is 2031-02-06.

What conditions does trial NCT04197934 study?

This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Glioblastoma, IDH-wildtype, Metastatic Malignant Neoplasm in the Central Nervous System, Anaplastic Astrocytoma, IDH-Wildtype.

What interventions are being tested in trial NCT04197934?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Biospecimen Collection - blood samples (PROCEDURE), Biospecimen Collection - CSF samples (PROCEDURE), EGFR/EGFRvIII Inhibitor WSD0922-FU (DRUG).

Who is sponsoring clinical trial NCT04197934?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04197934 being conducted?

This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Lung Cancer AJCC v8

All registered trials for this condition

Metastatic Lung Non-Small Cell Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.